What Is Vitamin B6 (PLP)? Normal vs Optimal Range Explained

The laboratory reference range for vitamin B6—5 to 50 ng/mL—spans a tenfold window that hides both functional deficiency at the low end and toxicity risk at the high end. A PLP level of 7 ng/mL is technically normal but already insufficient for aromatic amino acid decarboxylase (AADC), the enzyme that converts 5-HTP to serotonin and L-DOPA to dopamine. The CTD catalogs over 780 chemical-gene interactions involving PLP-dependent enzyme pathways, confirming that B6 participates in more enzymatic reactions than any other vitamin. Below 10 ng/mL, neurotransmitter synthesis is measurably impaired—patients in this range often present with depression, insomnia, and anxiety that clinicians attribute to psychological causes rather than checking a simple vitamin level. The optimal floor of 10 ng/mL ensures AADC, glutamate decarboxylase (GABA synthesis), and cystathionine beta-synthase (homocysteine clearance) all operate at full capacity.

PubMed indexes over 18,000 publications on pyridoxal phosphate and vitamin B6 in human health, spanning neurology, oncology, cardiovascular disease, and immune function. The upper optimal limit of 40 ng/mL exists for a critically important reason: chronic supplementation with pyridoxine (the inactive form) at doses above 100–200 mg per day causes sensory peripheral neuropathy—numbness, tingling, and balance problems that are identical to deficiency symptoms. This paradox occurs because excess pyridoxine competitively inhibits PLP at nerve receptor sites. FAERS documents over 1,800 adverse events associated with B6 supplementation, with peripheral neuropathy accounting for the majority. The active P5P form (pyridoxal-5-phosphate) appears safer at equivalent doses because it does not accumulate in the same way, but the optimal ceiling of 40 ng/mL provides a safety margin below the toxicity threshold.

Oral contraceptives are one of the most significant yet underrecognized B6 depleters. Estrogen increases tryptophan metabolism through the kynurenine pathway, which consumes PLP as a cofactor at every step. This diverts B6 away from serotonin synthesis—the mechanistic link between OCPs and the depression that affects an estimated 25 percent of women starting hormonal contraception. Isoniazid (TB treatment), levodopa (Parkinson's), hydralazine (blood pressure), and phenelzine (MAOI antidepressant) all deplete B6 through different mechanisms. The PYMAG trial demonstrated that magnesium combined with B6 was 24 percent more effective than magnesium alone for stress reduction, because B6 enhances intracellular magnesium transport. This synergy means that B6 deficiency can amplify magnesium deficiency symptoms and vice versa—both should be tested together in patients with mood or nerve complaints.